Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice-Reference-Cited by-同舟云学术

Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Published:2022-12 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Tural Deniz^ORCID,Arslan Cagatay,Selcukbiricik Fatih,Olmez Omer Fatih,Akar Emre^ORCID,Erman Mustafa,Ürün Yüksel^ORCID,Erdem Dilek,Karadurmus Nuri,Kilickap Saadettin

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Factsheets: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed: 2022.

3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;Von der Maase;J Clin Oncol,2005

4. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

5. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer;Vuky;J Clin Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atezolizumab/Nivolumab/Pembrolizumab;Reactions Weekly;2024-07-20